TDP-43 Cryptic Exon–Targeted ASOs to Restore Hippocampal Gamma Oscillations in Alzheimer's Disease
Mechanistic Foundation
TAR DNA-binding protein 43 (TDP-43) is a nuclear RNA-binding protein that plays essential roles in pre-mRNA splicing, mRNA stability, and transcriptomic regulation. In Alzheimer's disease (AD), TDP-43 pathology—characterized by cytoplasmic aggregates and nuclear clearance—affects approximately 50-60% of cases and is strongly associated with memory impairment and accelerated disease progression. While traditionally linked to frontotemporal dementia and amyotrophic lateral sclerosis, emerging evidence positions TDP-43 dysfunction as a critical driver of synaptic failure in AD through a mechanistically distinct pathway: dysregulated RNA splicing leading to cryptic exon inclusion.
Under physiological conditions, TDP-43 represses cryptic splice sites within intronic regions of pre-mRNA transcripts. This repression prevents the inclusion of anomalous coding sequences that would otherwise disrupt protein function. When TDP-43 becomes sequestered in cytoplasmic aggregates or undergoes pathological phosphorylation and truncation, nuclear TDP-43 levels decline, abrogating this surveillance function. The consequence is widespread cryptic exon inclusion across transcripts essential for neuronal viability and circuit function.
Among the most affected are transcripts encoding proteins critical for GABAergic interneuron operation, particularly those expressed in parvalbumin-positive (PV+) basket cells. These fast-spiking interneurons form perisomatic synapses onto pyramidal neurons and constitute the primary drivers of gamma-frequency oscillations (30-80 Hz). PV+ interneurons generate gamma rhythms through precisely timed, recurrent inhibition that entrains excitatory networks through feedback mechanisms. The generation of these oscillations requires faithful expression of proteins governing calcium buffering (parvalbumin itself), vesicle release machinery (synaptobrevin/VAMP2, complexin), and ion channel function (Kv3.1/Kcnc1, Cav3.1/Cacna1g).
Recent transcriptomic analyses in AD brain tissue and in vitro models of TDP-43 pathology have identified specific cryptic exons within transcripts including GAD1 (encoding glutamic acid decarboxylase 1, the enzyme synthesizing GABA), PVALB itself, and components of the SNARE complex. Inclusion of these cryptic exons introduces premature termination codons, triggers nonsense-mediated decay, or produces aberrant proteins that cannot fulfill their normal functions. The net effect is a reduction in functional GABAergic signaling, impaired PV+ interneuron firing precision, and destabilization of gamma oscillations.
Supporting Evidence
Research has demonstrated that TDP-43 knockdown in cultured neurons recapitulates key features of gamma oscillation deficits, with decreased power across the 30-80 Hz frequency band and disrupted synchronization across neuronal ensembles. Studies in mouse models expressing AD-linked TDP-43 mutations reveal that selective vulnerability of PV+ interneurons precedes broader neuronal loss, suggesting a cell-type-specific susceptibility to TDP-43-mediated splicing dysregulation.
Post-mortem studies of AD hippocampus have documented reduced PV immunoreactivity and altered GABAergic markers in regions critical for memory formation, including CA1 and the dentate gyrus. Critically, these changes correlate with decreased gamma oscillation power during memory encoding tasks. Functional imaging studies in living AD patients similarly demonstrate reduced hippocampal gamma activity during cognitive processing, supporting the translational relevance of this mechanism.
Preclinical work with ASOs targeting disease-associated splicing events has provided proof-of-concept for the therapeutic approach. ASOs designed against cryptic splice sites in C9orf72 transcripts—where GGGGCC repeat expansions cause TDP-43 mislocalization—have successfully restored normal splicing in patient-derived neurons. The pharmacological properties of ASOs favor CNS delivery following intrathecal administration, with demonstrated penetration into non-human primate hippocampus and cortex.
Therapeutic Strategy
Antisense oligonucleotides offer a precision therapeutic approach to this pathology. Well-designed ASOs are single-stranded DNA molecules (typically 12-25 nucleotides) that hybridize to specific pre-mRNA sequences via Watson-Crick base pairing. When directed against cryptic splice sites, ASOs sterically block access to the aberrant splice acceptor or donor sites, forcing the spliceosome to utilize the canonical junction and exclude the cryptic exon.
For PV+ interneurons specifically, the therapeutic ASO would require optimal delivery to this relatively sparse neuronal population (~10-15% of cortical interneurons). While systemic administration achieves broad CNS distribution, enhancing ASO uptake in PV+ cells may require conjugation to ligands for cell-surface receptors enriched on these neurons, such as the ErbB4 receptor, which is preferentially expressed in PV+ interneurons and mediates activity-dependent survival signaling.
A successful ASO intervention would restore normal splicing of TDP-43-regulated transcripts, recovering expression of functional proteins required for GABAergic transmission. In vivo, this would translate to improved synaptic inhibition onto pyramidal neurons, restored excitatory-inhibitory balance, and recovery of gamma oscillation generation. Downstream consequences would include enhanced temporal coordination of neural ensembles, improved pattern separation and memory consolidation, and restoration of cortical circuits subserving hippocampal-dependent learning.
Clinical Implications
The therapeutic potential of this approach extends beyond symptomatic benefit. Gamma oscillation deficits in AD likely contribute to circuit-level dysfunction that accelerates broader neurodegeneration through excitotoxicity and maladaptive plasticity. Restoring gamma rhythms may therefore provide neuroprotective effects beyond cognitive enhancement.
Patient stratification would be essential for clinical translation. TDP-43 pathology is not universal in AD—approximately 40-50% of patients lack detectable TDP-43 aggregates—and the cryptic exon splicing signature may be specific to those with TDP-43 involvement. Biomarker strategies, including cerebrospinal fluid TDP-43 species or PET ligands under development, could identify eligible patients.
Challenges and Limitations
Several obstacles must be addressed. First, the temporal window for intervention remains uncertain—PV+ interneuron dysfunction may become irreversible if prolonged. Second, ASO delivery to subcortical structures including the medial septum, which provides critical cholinergic and GABAergic inputs to the hippocampus, may be limiting. Third, TDP-43 pathology in AD often coexists with amyloid and tau abnormalities, and addressing only the TDP-43-mediated splicing deficit may yield limited benefits if other pathologies remain progressive.
Additionally, cryptic exon events may be numerous and variable across patients, necessitating comprehensive transcriptomic profiling to identify the full repertoire of disease-relevant splicing changes. Off-target effects of ASOs—while generally minimal with modern gapmer designs—require careful evaluation, particularly given the widespread RNA binding of TDP-43 and potential for widespread splicing alterations.
Integration with Disease Pathways
This hypothesis positions TDP-43 dysfunction as upstream of established AD pathological cascades. Gamma oscillation deficits precede and may accelerate amyloid plaque deposition, as evidenced by studies demonstrating that gamma frequency neural activity promotes microglial phagocytosis of amyloid. Tau pathology also reciprocally affects PV+ interneurons through hyperphosphorylated tau accumulation in these cells, suggesting potential synergies between TDP-43 and tau-targeted approaches.
The intersection with neuroinflammation warrants consideration: PV+ interneurons express complement proteins and participate in synaptic pruning, and their dysfunction may contribute to inflammatory cascades. Conversely, chronic neuroinflammation may exacerbate TDP-43 pathology through stress-activated kinases that promote TDP-43 phosphorylation and aggregation.
In summary, TDP-43 cryptic exon–targeted ASOs represent a mechanistically grounded therapeutic strategy to restore hippocampal gamma oscillations in AD. By correcting upstream RNA splicing dysregulation, this approach addresses a root cause of inhibitory circuit failure and offers potential for disease modification rather than mere symptom management.